Botanical species · safety record

Banisteriopsis caapi

The EFSA Compendium of Botanicals holds 7 constituent measurements for Banisteriopsis caapi. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Banisteriopsis caapi (Spruce ex Griseb.) Morton

7Constituent measurements

0Safety records

4Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Carboline alkaloids	Unspecified	—	≤ 1.95 Percent	—	Resolve DOI
Carboline alkaloids	Unspecified	—	≥ 0.05 Percent	—	Resolve DOI
Harmaline	Seed	Solvent extraction	≥ 0.03 Percent	Electrochemical tests (voltammetry and polarography)	Resolve DOI
Harmaline	Seed	Solvent extraction	≤ 0.83 Percent	Electrochemical tests (voltammetry and polarography)	Resolve DOI
Harmine	Seed	Solvent extraction	0.06 Percent	Electrochemical tests (voltammetry and polarography)	Resolve DOI
Carboline alkaloids	Aerial part of plants	Solvent extraction	—	Unspecified	No resolvable identifier
Harmine	Aerial part of plants	Solvent extraction	—	Unspecified	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Stankovic, Dalibor., Mehmeti, Eda., Svorc, Lubomir., Kalcher, Kurt. New electrochemical method for the determination of beta-carboline alkaloids, harmalol and harmine, in human urine samples and in Banisteriopsis caapi . Microchemical journal, 2015, vol. 118, p. 95-100. DOI
Gable, Robert S. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids . Addiction, 2007, vol. 102, no. 1, p. 24-34. DOI
Wishart, DS., Jewison, T., Guo, AC., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., Scalbert, A. Tetrahydroharmol (HMDB29835). Human metabolome database, 2012.
Wishart, DS., Jewison, T., Guo, AC., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., Scalbert, A. Harmalol (HMDB29838). Human metabolome database, 2012.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature